Related references
Note: Only part of the references are listed.Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract
Alex Ganetsky et al.
BONE MARROW TRANSPLANTATION (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A STAT3-based gene signature stratifies glioma patients for targeted therapy
Melanie Si Yan Tan et al.
NATURE COMMUNICATIONS (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells
Andrew M. Stein et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Y. Lai et al.
LEUKEMIA (2018)
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
Jianyu Weng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Christine E. Brown et al.
MOLECULAR THERAPY (2018)
Blastocyst-like structures generated solely from stem cells
Nicolas C. Rivron et al.
NATURE (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Lei Wang et al.
CANCER RESEARCH (2017)
Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6
Dae-Chul Cho et al.
NATURE COMMUNICATIONS (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Giedre Krenciute et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
Xinru Wei et al.
ONCOIMMUNOLOGY (2017)
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Nathan Singh et al.
CYTOTHERAPY (2017)
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
Elad Jacoby et al.
BLOOD (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor
Xuemei Jiang et al.
FRONTIERS IN IMMUNOLOGY (2016)
Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments
Wei Ye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8+ T Cell Function
Jan P. Boettcher et al.
CELL REPORTS (2014)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni et al.
NATURE REVIEWS CANCER (2012)
Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation
Isao Tawara et al.
CLINICAL CANCER RESEARCH (2011)
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells
Daniel T. Fisher et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2010)
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells
Christiane Stuhlmann-Laeisz et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
RM McLoughlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo
R Atreya et al.
NATURE MEDICINE (2000)